Posted by AGORACOM-JC
at 4:04 PM on Monday, August 16th, 2021
In an interview just over a month ago, Empower Clinics CEO Steve McAuley talked about how the Company is in full-blown growth mode that were best summarized as follows:
“Multiple opportunities have been percolating and I’m going to turn up the heat”
To this added seeing
“substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”.
Today McAuley and the team at Empower backed up those words with this announcement:
“The Company can now confirm the first new clinic launches will take place in September – location and ribbon cutting ceremonies to be announced – with rollouts of further locations continuing on a regular basis from that point forward.”
In today’s interview McAuley takes shareholders through a detailed overview of the foundation that has now been built, ready to launch and strong enough to catapult Empower into a completely new orbit. Watch this great interview. Welcome to the launch pad.
Posted by AGORACOM-JC
at 10:56 AM on Monday, August 16th, 2021
When it comes to small-cap companies, tech-focused Datametrex AI (DM: TSXV) (D4G: FSE) (DTMXF: OTCQB) is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.
In our newest interview with Datametrex, we sit down with CEO Marshall Gunter to discuss the company’s explosive H1-2021.
Financial Highlights include:
Revenue of $29,494,191 compared to revenue of $2,763,796 (same period 2020)
Net earnings of $10,410,485 compared to ($1,590,239).
EBITDA of $12,250,211 compared to ($1,197,679).
Cash balance significantly increased to $10,555,375 from $1,971,987 end of 2020.
In this episode, Dr. Steve Thayer, Dr. Reid Robison, and Vhari Macbeth discuss the concept of the self, multiple “selves”, and how we work with “selfhood” in psychedelic therapy.
Novamind has completed the sale of its investment in the Synthesis Institute, a strategic decision that enables Novamind to focus on the expansion of its network of clinics and clinical research sites located in the U.S.
“Novamind has experienced rapid growth in its two core businesses,” said Yaron Conforti, Chief Executive Officer and Director. “We’ve established a unique and scalable business model that serves clients at our clinics and drug developers at our research sites. We are now exclusively focused on the continued growth of our clinic and contract research organization businesses, with near-term expansion into other U.S. states and an exciting pipeline of clinical trials.”
New research indicates that ketamine, in combination with light, may be able to temporarily restore our brains back to the plasticity seen in critical growth periods. More research is needed, but initial studies are promising. “Whether or not ketamine and/or flickering light could enable temporary neural plasticity in other parts of the brain, perhaps to treat language disorders or learning disabilities, is also “an intriguing possibility and would need further experiments,” Siegert added.” We look forward to further research exploring the life changing potential of ketamine.
Zoe Cormier explores the benefits and costs of psychedelic therapy models—group vs solo. Strong anecdotal evidence is provided for the group therapy model. In practice, a case can be made for both, which is why the treatment protocols available at our Cedar Psychiatry clinics include group and solo participation. You can learn more about them here.
Posted by AGORACOM-JC
at 9:11 AM on Wednesday, August 11th, 2021
Liquid Avatar Technologies (LQID: CSE) (LQAVF: OTCQB) is a global blockchain, personal identity & Fintech solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified Self Sovereign Identity (“SSI”) through its Liquid Avatar platform (www.liquidavatar.com)
GENERALLY – Liquid Avatar Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.
SPECIFICALLY – Liquid Avatar Specializes In
Continuous Online Identity Verification
Personal Identity Management
Personal Data Monetization.
Liquid Avatar Credentials Ecosystem (LAVCE) enables people to share the results of a COVID test in a way that preserves their privacy and prevents fraud. The LAVCE platform can be integrated with healthcare facilities, testing labs, government agencies, schools, sports arenas, transportation, trade shows, and workplaces to confirm health status and assist efforts to reduce new outbreaks.
David Lucatch, CEO says it best, “It’s a privacy and security gamechanger, because there’s no need for a third party to access private health data to prove a test result is valid and from a trusted source. That’s huge. That solves the compliance problem.”
Sit back, relax and watch this powerful interview.
Posted by AGORACOM-JC
at 4:19 PM on Monday, August 9th, 2021
Most of us know drones for their recreational uses or perhaps even as simple commercial applications for things like real estate videos.
But the fact of the matter is that drone usage is about to go parabolic with huge corporations adopting them for a wide-use of applications that most never dreamed of such as:
To provide Internet connections in remote locations.
To collect crowd data.
In short, the drone industry is booming in ways people can’t imagine because the industry is shifting from the drones themselves (hardware) to drone technology and solutions (software)… and the one company that is delivering the most challenging applications is Draganfly Inc. (DPRO: NASDAQ) (DPRO: CSE)
DraganFly is an award-winning drone manufacturer and technology developer that is actually delivering some pretty incredible achievements, milestones and even history:
Established in 1998 DFLY is considered the oldest commercial drone company in the world
Built the first drone that saved a life
Boasts the first drone to be inducted into the Smithsonian National Air & Space Museum
Developing a Vaccine Drone Delivery Payload System (it’s way more complicated than just transporting vaccines)
Detect infectious conditions in a person from a distance of 190 feet
Conduct phenotyping, data collection and analysis by the USDA
With all of this under the Company’s belt, it’s easy to see why the company recently uplisted to the NASDAQ.
If you believe in the massive parabolic growth in the use of drones for almost everything we do in this world, or want to learn, then watch / listen to this powerful interview with Draganfly CEO and Chairman, Cameron Chell.
Where other treatments for depression have failed, ketamine has changed lives. Chief Medical Officer Dr. Reid Robison spoke to Leafly about how ketamine is changing mental healthcare.
“Ketamine is now emerging as a powerful catalyst to accelerate the healing and recovery process in individuals suffering from a wide array of mental health symptoms.”
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer, Vhari MacBeth, and Derick Moody explore the curious phenomenon of self-sabotage.
We are pleased to announce the appointment of Samantha DeLenardo as Vice President, Communications to lead Novamind’s communications, marketing and investor relations.
“At Novamind, we care deeply about the clients and families we serve,” said DeLenardo. “We are prepared to meet this transformative moment for psychedelics and mental health, thanks in large part to the courage and years of advocacy by people with lived expertise and medical practitioners. Novamind understands both the responsibility and opportunity before us, and I look forward to sharing the Company’s story with the world.”
In a big step forward for psychedelics, Usona Institute announced the groundbreaking of a Global Center in Psychedelic Science. The campus will “support a blend of disciplines in psychedelic science and education.” It’s another example of momentum building around the truly extraordinary therapeutic potential of psychedelics.
Words have not been minced. CEO Spencer Hawkswell comments on the current exemptions for the terminally ill in Canada, “We are going to be lobbying hard to get those regulations set into law to make sure that Canadians can realize their rights to psilocybin.” We look forward to that access expanding to all Canadians.
Posted by AGORACOM-JC
at 4:13 PM on Tuesday, August 3rd, 2021
Intema Solutions (ITM:TSXV) an emerging esports and iGaming company that is creating an Esports adventure like no other …. Create the world’s foremost esports and iGaming ecosystem.
The global online gambling market could potentially hit $1 TRILLION by the end of this decade. The obvious reasons include the following:
Exponential growth in the number of people online. Yet only 59% of the world means more to come.
Fast growth in the number of countries and jurisdictions legalizing gambling to collect tax revenue.
Esports was already the fastest growing sub-sector of digital entertainment, and Covid 19 has only accelerated this trend.
Biggest brands/tournament prizes / online audiences in the world … 500M +
The International Olympic Committee has recognized esports as a sport, and it will be a medal event at the 2022 Asian Games
Despite the vast amount of viewers, esports is still dramatically under-monetized relative to traditional sports. ITM believes wagering will play a major role in helping monetize this ever evolving platform.
Now sit back, relax and watch this powerful interview.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, discuss the art and science of psychedelic trip-sitting.
Gaining insurance coverage for off-label ketamine treatment of depression could help exponentially more people in their healing journeys. Off-label medicine isn’t covered by insurance.
“Our health care system does acknowledge and allow us to use medicines off-label. Probably 20 percent or more of all prescriptions are given that way.” – Novamind Chief Medical Officer Dr. Reid Robison
We are pleased to announce the completed the construction of a new clinic focused on integrative psychiatric care and clinical research in Draper, Utah. With the opening of the New Clinic, Novamind is on track to open four new locations in Utah by September 2021, doubling the size of its network to eight clinics.
“We are on a mission to reduce suffering and optimize wellness and are committed to shaping the future of psychedelic medicine in a responsible and accessible way,” said Dr. Reid Robison, Novamind’s Chief Medical Officer.
In an article for Harvard Health, Peter Grinspoon, MD, covers how psychedelics work, evidence for using psychedelics medicinally and the pros and cons. It’s an interesting read given his personal history with psychedelics, which dates back to when he was 14 and reading “Psychedelic Drugs Reconsidered.” He remembers the book urging “an open-minded reappraisal about the therapeutic potential of this class of drugs.” Anyone involved in psychedelics knows that not all conversations on the topic are open-minded. It’s why part of the mission to provide safe, legal access to psychedelics also includes an educational component. The more we can destigmatize psychedelics, the faster we can continue to push the renaissance forward.
Have you ever wondered what psychedelic therapy looks like? This article provides an insight into that process. “You don’t just get thrown into it,” (Jennifer) Mitchell says. “It’s not Burning Man or something. It’s very thoughtful.” And it’s something we take very seriously at our Cedar Psychiatry clinics. We recently posted a blog about psychedelics and safety considerations. Read it here.
Chief Medical Officer Dr. Reid Robison explains the three pillars of Ketamine therapy and the steps we take to prevent misuse.
“I’ve never had a client who we’ve done the appropriate process with who has entered into a troubled relationship with ketamine through the course of their treatment.”
Our Chief Medical Officer joins Health Professional Radio to discuss psychedelic medicine and our rapid expansion phase as we grow our network of clinics, research sites and therapeutic retreats specialized in psychedelic medicine.
“We’re expanding even more with the need that has come up through the pandemic and the willingness to look towards new and improved ways of approaching our mental health”
We are pleased to announce that we have submitted our application to have our common shares posted for trading on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.
“Having the Company’s common shares posted for trading on the OTCQB and providing a more efficient way of trading our shares will be an important milestone in our strategy of building awareness and enhancing accessibility amongst United States investors looking for exposure to the growth potential of Novamind’s mental health and psychedelic medicine business,” said Yaron Conforti, CEO and Director of Novamind.
A groundbreaking Yale study has uncovered a new dimension in understanding how psychedelics affect us: with small, physical changes to the brain. The study tracked how psilocybin, the active molecule in psychedelic mushrooms, not only has significant and long-lasting effects on mood but actually stimulates growth of new neuronal connections within the brain.
Governments around the world accelerated the clinical research process to develop vaccines for the Covid-19 health crisis. So why can’t we do the same for drugs to treat the mental health crisis? Monnica Williams and Morgan Campbell argue the point in the Baltimore Sun, comparing the investment in mental health treatment with physical health treatment: Investment in psychiatric therapies has remained very low compared to the burden of diseases, with $1.80 per $1,000 in disease burden for major depression and $0.40 for bipolar disorder compared to $9.40 for COPD, $7.60 for diabetes and $75.50 for cancer.
The popularity of using ketamine as a psychedelic treatment is only growing, according to ABC News. Less than 60 ketamine clinics existed in the United States in 2015. In 2018, that number climbed to over 300. With over 7,000 ketamine treatments to date, Novamind remains one of the busiest and most experienced ketamine practices in America.
Michael Pollan, the award-winning journalist who wrote “How to Change Your Mind,” a comprehensive examination of psychedelics history and his personal experience, is back. His new book contrasts the effects of three plant-based substances: caffeine, opium and mescaline. His section on mescaline further destigmatizes psychedelics through a critical and journalistic lens.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.
Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.
“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.
We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.
“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.
Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly.
While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.
